Tay-
Sachs or Sandhoff disease results from a deficiency of either the
- or the
-subunits of
-hexosaminidase A, respectively. These evolutionarily related subunits have been grouped with the "Family20" glycosidases. Molecular modeling of human hexosaminidase has been carried out on the basis of thethree-dimensional structure of a bacterial member of Family 20,
Serratia marcescens chitobiase. Theprimary sequence identity between the two enzymes is only 26% and restricted to their active site regions;therefore, the validity of this model must be determined experimentally. Because human hexosaminidasecannot be functionally expressed in bacteria, characterization of mutagenized hexosaminidase must becarried out using eukaryotic cell expression systems that all produce endogenous hexosaminidase activity.Even small amounts of endogenous enzyme can interfere with accurate
Km or
Vmax determinations. Wereport the expression, purification, and characterization of a C-terminal His
6-tag precursor form of hexosaminidase B that is 99.99% free of endogenous enzyme from the host cells. Control experiments arereported confirming that the kinetic parameters of the His
6-tag precursor are the same as the untaggedprecursor, which in turn are identical to the mature isoenzyme. Using highly purified wild-type and Arg
211Lys-substituted hexosaminidase B, we reexamine the role of Arg
211 in the active site. As we previouslyreported, this very conservative substitution nevertheless reduces
kcat by 500-fold. However, the removalof all endogenous activity has now allowed us to detect a 10-fold increase in
Km that was not apparent inour previous study. That this increase in
Km reflects a decrease in the strength of substrate binding wasconfirmed by the inability of the mutant isozyme to efficiently bind an immobilized substrate analogue,i.e., a hexosaminidase affinity column. Thus, Arg
211 is involved in substrate binding, as predicted by thechitobiase model, as well as catalysis.